Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cortex (Cor) [formerly CORX] -- Ignore unavailable to you. Want to Upgrade?

To: Rick Costantino who wrote (588)	10/19/1998 5:12:00 PM
From: mammoth	Read Replies (1) \| Respond to of 1255

Very disappointing day for CORX. Only positive thing is it can only go down 1/2 point max now. I hope they get that partner soon.

To: Rick Costantino who wrote (588)	2/16/1999 1:12:00 AM
From: James M. Bash	Read Replies (1) \| Respond to of 1255

CORX featured in MSNBC article: msnbc.com

To: Rick Costantino who wrote (588)	2/16/1999 8:31:00 PM
From: James M. Bash	Read Replies (2) \| Respond to of 1255

CORX slated to receive $8m+ cash from Organon! "Subsequent to December 31, 1998, the Company entered into a research collaboration and exclusive worldwide license agreement with NV Organon ("Organon"), a pharmaceutical business unit of Akzo Nobel (The Netherlands). The agreement will allow Organon to develop and commercialize the Company's proprietary Ampakine(R) technology for the treatment of schizophrenia and, upon Organon's election, for the treatment of depression. In connection with the agreement, the Company received $2,000,000, representing an up-front licensing payment. The agreement includes research support payments of up to $3,000,000 per year for two years (subject to Cortex providing agreed-upon levels of research) and milestone payments, plus royalty payments on worldwide sales."